Meta-analysis in genetics and genomics

Darlene Goldstein

École Polytechnique Fédérale de Lausanne

Joint work with Mauro Delorenzi, Thierry Sengstag and Ruth Luthi-Carter

Joint CSPS/IMS Meeting, Beijing 9 July 2005



Outline

- The problem an illustration
- What is meta-analysis and why might it help
- Why meta-analysis might not be straightforward study heterogeneity
- Combining information across linkage studies 'simple', 'worst' case scenarios
- Combining information across microarray studies 'simple', 'worst' case scenarios
- Concluding remarks



A study is carried out to examine mean IBD sharing between concordant obese (BMI > 35) and discordant sib pairs at 8 markers in the human OB gene region



- A study is carried out to examine mean IBD sharing between concordant obese (BMI > 35) and discordant sib pairs at 8 markers in the human OB gene region
- A second study performs multipoint tests of linkage between obesity-related quantitative traits and 15 markers on sibship data from pedigrees ascertained on a type II diabetic proband



- A study is carried out to examine mean IBD sharing between concordant obese (BMI > 35) and discordant sib pairs at 8 markers in the human OB gene region
- A second study performs multipoint tests of linkage between obesity-related quantitative traits and 15 markers on sibship data from pedigrees ascertained on a type II diabetic proband
- A third study investigates a single marker (different from those of Studies 1 and 2) in 400 sib pairs using Haseman-Elston regression



- A study is carried out to examine mean IBD sharing between concordant obese (BMI > 35) and discordant sib pairs at 8 markers in the human OB gene region
- A second study performs multipoint tests of linkage between obesity-related quantitative traits and 15 markers on sibship data from pedigrees ascertained on a type II diabetic proband
- A third study investigates a single marker (different from those of Studies 1 and 2) in 400 sib pairs using Haseman-Elston regression
- Question: What is the evidence in favor of linkage between obesity and the OB gene?



What is meta-analysis?

- Statistical methods for combining *results* of independent studies addressing related questions
- Several different methods, including
 - Comparative binary outcomes: combining odds ratios
 - Continuous outcomes: combining parameter estimates via *fixed effects* or *random effects models*
 - Any outcome type: combining *p-values* from hypothesis tests about the data
- Alternative to meta-analysis: combining (or pooling)
 data for the analysis
- Not always appropriate to pool Simpson's paradox



Why might meta-analysis help?

- To obtain *increased power*
- Studies with small sample sizes are less likely to find effects even when they exist
- Integration-driven discovery' (IDD; Choi et al., Bioinformatics 2003)
- Given the small (but increasing) size of many linkage and microarray experiments, meta-analysis might be considered a *natural approach* to the problem of integrating results



Combining information

To combine information across studies, we consider

- Combining (pooling) *raw data* and analyzing as a single data set (suggested in the linkage context by Lander and Kruglyak, *Nat. Genet.* 1995)
 - may not be possible *e.g.* raw data may not be available
 - may not be sensible *e.g.* too many differences between the studies
 - may not be feasible e.g. limited computing power
- Combining parameter estimates
 - Fixed effects model (FE)
 - Random effects model (RE)
- Combining *p*-values



FE vs. RE meta-analysis (I)

- FE and RE are both ways to obtain a single, combined parameter estimate from a set of estimates obtained from different studies
- The combined estimates are weighted averages
- FE assumes there is *no heterogeneity between results* of the different studies
- If the results are heterogeneous, then there is assumed to be no single underlying value of HD effect but rather a distribution of values
- Differences among study results are considered to arise from *inter-study variation* of true effect size as well as chance variation



FE vs. RE meta-analysis (II)

- In FE meta-analysis, each individual study estimate receives weight inversely proportional to its variance
- RE meta-analysis assumes that individual studies may be estimating *different* treatment effects
- Study weights are adjusted to take into account the additional variability τ^2 between studies: $w_i^* = \frac{1}{(1/w_i) + \hat{\tau}^2}$
- When the additional variability between studies is 0, then the RE model reduces to the FE model
- If assume *normality* of the estimates, can get *p*-values (and *q*-values)



Fisher combined *p***-values**

- Other methods for combining results focus on p-values
- Usually preferable to combine data or parameter estimates, but sometimes impossible – e.g., only p-values available, no parameter estimates given
- Several methods for combining *p*-values, an old (1930s) and commonly used method is due to Fisher
- The Fisher summary test statistic $\mathbf{S} = -2\sum_{i=1}^{k} \log(p_i)$
 - The theoretical null distribution of S should be χ^2_{2k}
 - Rhodes *et al.* (*Cancer Res.* 2002) obtain a *p*-value for S by resampling



Problem: study heterogeneity

In general, studies may vary in

- scientific research goals
- population of interest
- design
- quality of implementation
- subject inclusion and exclusion criteria
- baseline status of subjects
- treatment dosage and timing
- management of study subjects
- outcome definition or measures
- statistical methods of analysis



Heterogeneity in genetics

In the *linkage context*, sources of heterogeneity include

- different family structures
- different ascertainment rules (*e.g.* concordant sib pairs, discordant sib pairs, families with at least one affected)
- genetic heterogeneity between study populations
- different genetic markers across studies
- different statistical tests of linkage
- phenotype definition



Heterogeneity in genomics

In the *microarray context*, sources of heterogeneity include

- differences in the technology used for the study
- heterogeneity of measured expression from the same probe occurring multiple times on the array
- multiple (different) probes for the same gene
- variability in probes used by different platforms
- different gene expression measures, even with the same technology



Linkage: simple case

- Simulated data from Genetic Analysis Workshop (GAW) 11
- *2 genetically distinct, clinically identical* diseases with *mild* and *severe* forms
 - Single locus with 3 alleles, interacting with environmental factor
 - 2 epistatically interacting loci, associated with an allele at one of the marker loci
- Family linkage and disease data from 3 populations, each with different genetic parameters
- Genotypes at 300 polymorphic markers
- 4 studies (2 from same population with *different* ascertainment schemes)



Analyses: Simple case

- Described in detail in
 - Goldstein, Sain, Guerra and Etzel Gen. Epi. 1999
 - Guerra, Etzel, Goldstein and Sain Gen. Epi. 1999
- Mean IBD sharing (2-point sib-pair analysis)
 - Pooling raw data
 - FE meta-analysis
 - RE meta-analysis
 - Fisher combined *p*-value
- Multipoint NPL
 - Pooling raw data
 - Fisher combined *p*-value
- Assumption: all studies make p-values available if at least one study found a 'significant' result

Results: Simple case

- When possible, better to combine raw data or parameter estimates than to combine p-values
- Combining *p*-values led to more false positives and missed more true linkages
- If results heterogeneous, may not be possible to combine *p*-values (based on our assumption regarding *p*-value availability)
- Multipoint analysis had *fewer false positives* than 2-point



Linkage: worst case (I)

- Allison and Heo (*Genetics* 1998) combined *p*-values across obesity linkage studies (as in the example)
 - Not always straightforward to obtain the relevant p-values
 - In these cases, they used *ad hoc* methods to obtain a single *p*-value for each study
- Wise, Lanchbury and Lewis (Ann. Hum. Genet. 1999) proposed the Genome Search Meta-analysis method, GSMA
 - Also sometimes called Genome Scan Meta-analysis
 - Ranks genome intervals according to evidence for linkage, combines these ranks across studies and assesses significance



Linkage: worst case (II)

- Loesgen et al. (Gen. Epi. 2001) proposed weighting multipoint NPL scores
 - Applied to GAW 12 data
 - In a simulation study, Dempfle and Loesgen (Ann. Hum. Genet. 2004) found favorable power properties compared to Fisher combined *p*-values, GSMA
- Etzel and Guerra (*Am. J. Hum. Genet.* 2002) combined H-E regression slopes via WLS to estimate location of a QTL
 - Also provide SEs and test for linkage
 - Can also be applied to other statistics



Microarray: simple case

- Data from two experiments on the R6/2 mouse, a mouse model of human Huntington's disease (HD)
- Looked at *effects on gene expression of different drugs* on HD and normal (WT) mice
- Each experiment is a 2x2 factorial layout
 - drug/placebo treatment
 - HD/WT mouse
- Consider only the *control groups* for the two studies
 - Study I has 8 controls, Study II has 6 controls
 - In each study, half of the mice HD, half WT
 - Experiments carried out by the same laboratory a few months apart, using the same protocols
 - Affymetrix MOE 430A; 22,690 probe sets ('genes')



Analyses: simple case

- Combined data analysis: pretend all the data are from one study and analyze that single (combined) data set (14 mice)
- Meta-analysis methods: combine results from the two individual studies by 3 methods
 - Fixed effects model (FE)
 - Random effects model (RE)
 - Combining *p*-values (Fisher)
 - χ^2 assumption
 - Resampling *p*-value



Combined data analysis

- Consider all 14 chips as a single data set from the same experiment
- RMA all 14 chips together (all passed quality check)
- Normalization: would like to remove (all) artifactual differences between chips, leaving (only) true biological differences
- Identify DE genes using (single gene) linear modeling approach (limma, Smyth 2004)
 - Model A: $y = \beta_0 + \beta_{HD}I_{\{HD=1\}} + \epsilon$
 - Model B: $y = \beta_0 + \beta_{HD}I_{\{HD=1\}} + \beta_{batch}I_{\{batch=1\}} + \epsilon$
 - Model C: $y = \beta_0 + \beta_{HD}I_{\{HD=1\}} + \beta_{batch}I_{\{batch=I\}} + \beta_{HD \times batch}I_{\{HD \times batch=1\}} + \epsilon$



Meta-analysis

First analyze each experiment as a separate study

- Separately RMA the 2 sets (8 chips, 6 chips)
- Within each study identify DE genes by the model $y = \beta_0 + \beta_{HD}I_{\{HD=1\}} + \epsilon$
- Heterogeneity analysis (χ^2 test)
- If appropriate, combine (via FE, RE, Fisher)



Results: Persistent batch effects

Ward, 1 – cor, all genes



Combined data RMA dendrogram

Results: HD effects

HD q-values





Results: Stratification by het status

	Sig.	at FDR =	= .10	Sig.	at FDR =	= .05	Sig. at FDR = .01		
Method	All	Hom.	Het.	All	Hom.	Het.	All	Hom.	Het.
С	0.07	0.06	0.19	0.03	0.03	0.12	0.01	0.01	0.05
FE	0.18	0.17	0.38	0.12	0.11	0.30	0.06	0.05	0.21
RE	0.06	0.06	0.01	0.04	0.04	0.00	0.02	0.02	0.00
FX	0.08	0.06	0.70	0.04	0.03	0.29	0.01	0.01	0.10
FR	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
FR Number	(5)	(3)	(2)	(3)	(2)	(1)	(3)	(2)	(1)



Results: Pairwise agreement



Symbol	0	1	2	3	4	5	6	7	8	9
Pair	FE	FE	FE	FE	FX	FX	FX	С	С	RE
	FR	RE	С	FX	RE	FR	С	FR	RE	FR



Microarray: worst case

- Irizarry et al. (Nat. Methods 2005) carried out a platform comparison that incorporated an assessment of lab effect using a random effects model
 - Importance of using *relative* measures
 - See also Cox and Solomon Components of Variance
- Rhodes et al. (Cancer Res. 2002) combine permutation t-test p-values for genes measured in all studies
- Choi et al. (Bioinformatics 2003) consider FE and RE meta-analysis of standardized mean differences between two sample types



Concluding remarks (I)

- Caveat: Pooling raw data not always possible or sensible
 - Even in the 'simple' cases several decisions required before data analysis can proceed
 - In sufficiently homogeneous cases pooling raw data probably best
 - Publicly accessible databases for obtaining raw data
- Value of exploring methods on *simple cases*
 - Can give some insight into performance in the more complicated scenarios



Concluding remarks (II)

- In the microarray simple case study here, we compare results from different methods of analysis; can't assess method performance or robustness – 'known truth' not available
 - Biological follow-up on many genes (currently in progress)
 - Simulation studies may provide some insight (Stevens and Doerge, *BMC Bioinformatics* 2005)
- Study 'batch' effects
 - Normalize within study prior to combining
 - Account for study when pooling, *e.g.* random effect (Irizarry *et al.*, *Nat. Methods* 2005)



Concluding remarks (III)

- Between and within lab variability should be examined where possible
 - What covariates might be associated with measurements
 - Can suggest improvements in lab procedures
- Implications for *large single center studies*, where
 - Patients recruited over time
 - Arrays not hybridized at the same time
 - Different technicians carry out the work
 - etc. ...



Acknowledgements

Collaborators

- Mauro Delorenzi and Thierry Sengstag
 - Institut Suisse de Recherche Expérimentale sur le Cancer and Swiss Institute of Bioinformatics
- Ruth Luthi-Carter
 - École Polytechnique Fédérale de Lausanne, Laboratoire de neurogénomique fonctionnelle
- **R. J. Ferrante, J. K. Kubilus for providing samples**

Grant Support

- Swiss National Science Foundation
- US National Institutes of Health

